Skip to main content

Table 2 Assessment method of administration of included studies

From: Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients

Study Trial group (N) Control Group(N) Interventions (Groups) Treatment cycle Termination of treatment
Cisplatin+IL-2 Cisplatin alone
Changjie H 2001 [15] 30 30 Cisplatin: 50 mg + NS 50 mL
IL-2: 2 million units+NS 30 mL
Cisplatin 50 mg + NS 50 mL 1/week > 2 cycles, or
pleural effusion disappeared
Xiuzhi Y 2001 [16] 40 20 Cisplatin: 40 mg + NS 50 mL
IL-2: 2 million units+NS 30 mL
Cisplatin 40 mg + NS 50 mL 1/week > 2 cycles, or
pleural effusion disappeared
Zhuo S 2004 [17] 32 30 Cisplatin: 60 mg + NS 30 mL
IL-2: 2 million units+NS 30 mL
Cisplatin 60 mg + NS 30 mL 1/week > 2 cycles, or
pleural effusion disappeared
Junyan W 2005 [18] 48 34 Cisplatin: 80-100 mg + NS 30 mL
IL-2: 2–3 million units+NS 30 mL
Cisplatin 80-100 mg + NS 30 mL 1/week > 3 cycles, or
pleural effusion disappeared
Haiying X 2009 [19] 35 28 Cisplatin: 60 mg + NS 40 mL
IL-2: 2 million units+NS 20 mL
Cisplatin 60 mg + NS 40 mL 1/week > 2 cycles, or
pleural effusion disappeared
Xiaoxia H 2009 [20] 37 35 Cisplatin: 100 mg + NS 50 mL
IL-2: 1 million units+NS 30 mL
Cisplatin 100 mg + NS 50 mL 1/week > 2 cycles, or
pleural effusion disappeared
Lizheng C 2009 [21] 46 40 Cisplatin: 50 mg + NS 50 mL
IL-2: 2–3 million units+NS 50 mL
Cisplatin 50 mg + NS 50 mL 1/week > 2 cycles, or
pleural effusion disappeared
Jinguang C 2009 [22] 31 31 Cisplatin: 60 mg + NS 50 mL
IL-2: 2 million units+NS 50 mL
Cisplatin 60 mg + NS 50 mL 1/week > 3 cycles, or
pleural effusion disappeared
Junfeng W 2010 [23] 41 41 Cisplatin: 60-80 mg + NS 50 mL
IL-2: 2–3 million units+NS 50 mL
Cisplatin 60-80 mg + NS 50 mL 1/week > 3 cycles, or
pleural effusion disappeared
Jingping Z 2010 [24] 63 61 Cisplatin: 40-60 mg + NS 50 mL
IL-2: 1 million units+NS 40 mL
Cisplatin 40–60 + NS 40 mL 1/week > 3 cycles, or
pleural effusion disappeared
Cheng X 2010 [25] 31 31 Cisplatin: 60-100 mg + NS 50 mL
IL-2: 1–2 million units+NS 50 mL
Cisplatin 60-100 mg + NS 50 mL 1/week > 1 cycles, or
pleural effusion disappeared
Fang S 2011 [26] 30 30 Cisplatin: 60 mg + NS 40 mL
IL-2: 2 million units+NS 40 mL
Cisplatin 60 mg + NS 40 mL 1/week > 3 cycles, or
pleural effusion disappeared
Xueling L 2011 [27] 34 34 Cisplatin: 60 mg + NS 50 mL
IL-2: 2 million units+NS 50 mL
Cisplatin 60 mg + NS 50 mL 1/week > 3 cycles, or
pleural effusion disappeared
Yan Q 2011 [28] 41 35 Cisplatin: 60 mg + NS 40 mL
IL-2: 2 million units+NS 40 mL
Cisplatin 60 mg + NS 40 mL 1/week > 3 cycles, or
pleural effusion disappeared
Li J 2013 [29] 38 35 Cisplatin: 60-80 mg + NS 50 mL
IL-2: 1–2 million units+NS 20 mL
Cisplatin 60-80 mg + NS 50 mL 1/week > 3 cycles, or
pleural effusion disappeared
Lijie H 2014 [30] 30 30 Cisplatin: 40-60 mg + NS 50 mL
IL-2: 2 million units+NS 50 mL
Cisplatin 40-60 mg + NS 50 mL 1/week > 2 cycles, or
pleural effusion disappeared
Miao H 2016 [31] 31 30 Cisplatin: 60 mg + NS 50 mL
IL-2: 2–3 million units+NS 30 mL
Cisplatin 60 mg + NS 50 mL 1/week > 3 cycles, or
pleural effusion disappeared
Baohua Y 2017 [32] 33 33 Cisplatin: 70-80 mg + NS 50 mL
IL-2: 2–3 million units+NS 30 mL
Cisplatin 70-80 mg + NS 50 mL 1/week > 3 cycles, or
pleural effusion disappeared
  1. N numbers of patients, IL-2 interleukin-2, NS normal saline